Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation

Turk, Viktorija Erdeljić

doi:10.1016/j.clim.2021.108748

Cited by 31 publications

(38 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More research is needed to identify the cause of the potentially increased rate of anaphylaxis to COVID-19 vaccines, but polyethylene glycol (PEG) 2000, an excipient used to cover the lipid nanoparticles (LNSs) that contain the mRNA in the COVID-19 mRNA vaccines, is deemed to be the possible culprit of anaphylactic reactions [120].…”

Section: Post-marketing Evidencementioning

confidence: 99%

“…Due to the rarity of severe allergic reactions to COVID-19 vaccination and the not yet elucidated mechanisms underlying those adverse reactions, diagnostic procedures to predict allergic reactions to COVID-19 vaccines are not consistently recommended [120,127]. Because of the hypothesis of a potential contribution of PEG in allergic reactions to COVID-19 mRNA vaccines, some individuals may be offered skin testing for PEG sensitisation before vaccination [120].…”

Section: Recommendation For Covid-19 Vaccinationmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety

et al. 2021

View full text Add to dashboard Cite

Section: Post-marketing Evidencementioning

confidence: 99%

Section: Recommendation For Covid-19 Vaccinationmentioning

confidence: 99%

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety

et al. 2021

View full text Add to dashboard Cite

“…High-molecular weight PEG seems to pose a higher risk for this adverse event [22]. Usually, type I reactions are IgE mediated, but other mechanisms of anaphylaxis have been considered as well [23,24].…”

Section: Anaphylaxismentioning

confidence: 99%

Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review

Wollina

Chiriac

Kocic

et al. 2021

Wien Med Wochenschr

View full text Add to dashboard Cite

Vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV‑2) has become a major tool in the battle against the coronavirus disease 2019 (COVID-19) pandemic. Numerous products have been developed and more are to come. Vaccination success varies greatly between different countries. There are a number of different vaccine types, such as mRNA, DNA vaccines, adenovirus vector vaccines, and full-length spike protein nanoparticles with a special matrix. The different types may also cause a different spectrum of adverse events. With mass vaccination, post-marketing surveillance for product safety becomes increasingly important. In this review, we discuss possible hypersensitivity and cutaneous adverse events related to SARS-CoV‑2 vaccination—from local reactions like COVID arm to systemic and severe reactions like anaphylaxis. Vaccination may also induce or exacerbate preexisting disorders such as herpes zoster infection. This review should provide information to tailor, whenever possible, vaccination to patients’ needs. It is a contribution to patient safety as well. There is general consensus that the benefits of SARS-CoV‑2 vaccination currently outweigh the risks of possible adverse events.

show abstract

“…chilblain‐like lesions, morbilliform rashes and vasculitis) SARS‐CoV‐2 vaccines appear to have also the potential to induce a broad spectrum of cutaneous adverse events. 1 , 2 , 3 , 4 , 5 In this review article, 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , …”

Section: Introductionmentioning

confidence: 99%

Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience

Gambichler

Boms²,

Susok

et al. 2021

Acad Dermatol Venereol

176

237

View full text Add to dashboard Cite

There is growing evidence that not only the novel coronavirus disease (COVID‐19) but also the COVID‐19 vaccines can cause a variety of skin reactions. In this review article, we provide a brief overview on cutaneous findings that have been observed since the emerging mass COVID‐19 vaccination campaigns all over the world. Unspecific injection‐site reactions very early occurring after the vaccination are most frequent. Type I hypersensitivity reactions (e.g. urticaria, angio‐oedema and anaphylaxis) likely due to allergy to ingredients may rarely occur but can be severe. Type IV hypersensitivity reactions may be observed, including delayed large local skin lesions (“COVID arm”), inflammatory reactions in dermal filler or previous radiation sites or even old BCG scars, and more commonly morbilliform and erythema multiforme‐like rashes. Autoimmune‐mediated skin findings after COVID‐19 vaccination include leucocytoclastic vasculitis, lupus erythematosus and immune thrombocytopenia. Functional angiopathies (chilblain‐like lesions, erythromelalgia) may also be observed. Pityriasis rosea‐like rashes and reactivation of herpes zoster have also been reported after COVID‐19 vaccination. In conclusion, there are numerous cutaneous reaction patterns that may occur following COVID‐19 vaccination, whereby many of these skin findings are of immunological/autoimmunological nature. Importantly, molecular mimicry exists between SARS‐CoV‐2 (e.g. the spike‐protein sequences used to design the vaccines) and human components and may thus explain some COVID‐19 pathologies as well as adverse skin reactions to COVID‐19 vaccinations.

show abstract

Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation

Cited by 31 publications

References 32 publications

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety

Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review

Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience

Contact Info

Product

Resources

About